Aimmune Therapeutics Growth, Revenue, Number of Employees and Funding

Overview

Location:
Total Funding:$398.7M
Industry:Biotech
Founded:2011
Lead Investor(s):KKR
Press

City Ranking

Industry Ranking

State Ranking

Growjo 10k Ranking

Revenue & Financials

  • Aimmune Therapeutics's revenue is currently $30.7M per year.
  • Aimmune Therapeutics received $170.0M in venture funding in January 2019.
  • Aimmune Therapeutics's revenue per employee is $120353
  • Aimmune Therapeutics's total funding is $398.7M.

Employee Data

  • Aimmune Therapeutics has 255 Employees.
  • Aimmune Therapeutics grew their employee count by 29% last year.
  • Aimmune Therapeutics currently has 51 job openings.

What Is Aimmune Therapeutics?

Aimmune Therapeutics, a clinical-stage biopharmaceutical company, is developing desensitization treatments to help protect people with food allergies by potentially reducing the risk of allergic reactions, making accidental exposures to food allergens less dangerous. We are currently conducting Phase 3 studies of our lead product, AR101 for the treatment of peanut allergy. Aimmune is located in Brisbane, California - the heart of San Francisco's biotechnology hub - with additional offices in the Kings Cross area of London and in Raleigh, North Carolina.

keywords:Biotechnology,Food & Beverages,Healthcare,Pharmaceuticals

255

Number of Employees

$30.7M

Revenue (est)

51

Current Jobs

29%

Employee Growth %

$398.7M

Total Funding

N/A

Valuation

N/A

Accelerator

B2B

Type

Similar Companies

NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
Mission Bio
$7.4M6944%
Rigel Pharmaceu...
$40.5M2714%
ProTrials Resea...
$25.6M1703%
Advanced Cell D...
$23.9M1668%
CellMax Life
$10M379%$9M
Atreca
$10.7M8117%
Full Spectrum A...
$5.7M395%
Pipette.com/Acc...
N/AN/A
Irvine Scientif...
$29.1M2059%
Talis Biomedica...
$8.1M544%

Aimmune Therapeutics News

20-Mar-19 - Aimmune down 5% on FDA timeline for AR101

Aimmune Therapeutics (AIMT -4.8%) is down on below-average volume in reaction to the FDA's review period for AR101 for peanut allergy.

20-Mar-19 - Will Aimmune Therapeutics, Inc. (AIMT) Short Squeeze Soon?

The stock of Aimmune Therapeutics, Inc. (NASDAQ:AIMT) is a huge mover today! The stock decreased 4.56% or $1.07 during the last trading

28-Feb-19 - Aimmune Therapeutics' (AIMT) CEO Jayson Dallas on Q4 2018

Aimmune Therapeutics, Inc. (NASDAQ:AIMT) Q4 2018 Earnings Conference Call February 28, 2019 5:00 PM ET. Company Participants.

Aimmune Therapeutics Funding

DateAmountRoundLead InvestorsReference
2016-11-07$145.0MNestlé Health SciencNestlé Health ScienceArticle
2018-02-21$177.5MUndisclosedArticle
2018-11-29$98.0MUndisclosedNestlé Health ScienceArticle
2019-01-07$170.0MUndisclosedKKRArticle

Aimmune Therapeutics Executive Hires

DateNameTitleReference
2015-10-12Howard RaffConsultantArticle
2016-04-06Douglas SheehyGeneral Counsel/SecretaryArticle
2016-06-22Daniel AdelmanChief Medical OfficerArticle
2017-04-14Eric BjerkholtChief Financial OfficerArticle
2018-06-12Jayson DallasPresident and Chief Executive OfficerArticle
2019-01-21Andrew OxtobyChief Commercial OfficerArticle